Managers / Q2 2025 · view latest →
Vantage Consulting Group Inc
CIK 0001843547 · 3500 PACIFIC AVE, VIRGINIA BEACH, VA, 23451 · 757-491-1200
Summary
Vantage Consulting Group Inc reported $6M in U.S.-listed holdings across 3 positions for Q2 2025.
The portfolio is heavily concentrated: BW alone accounts for 40.5% of reported value.
Compared with Q1 2025, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 68.1% · $4M
- Other · 31.9% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| FGENEURFibrogen, Inc | SOLD OUT | −195.7K | 0 | −$60,650 | $0 |
| ADC Therapeutics SA | TRIMMED | −167.7K | 683.0K | +$630,896 | $2M |
| BWBabcock & Wilcox Enterprises Inc. | HELD | +0 | 2.42M | +$699,973 | $2M |
| CBUSCibus, Inc. | HELD | +0 | 1.14M | −$560,535 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BWBabcock & Wilcox Enterprises Inc.history → | COM | 40.54% | $2M | 2.42M |
| 2 | ADC Therapeutics SA | COM | 31.92% | $2M | 683.0K |
| 3 | CBUSCibus, Inc.history → | COM | 27.53% | $2M | 1.14M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2025 | $20M | 3 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $11M | 3 | Nov 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $6M | 3 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $5M | 4 | May 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $10M | 5 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $11M | 4 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $135M | 191 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $157M | 212 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $149M | 208 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $149M | 200 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $174M | 216 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $176M | 231 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $169M | 212 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $171M | 213 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $178M | 213 | Aug 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $256M | 215 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $372M | 231 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $467M | 206 | Nov 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $575M | 211 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $498M | 99 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.2B | 1,884 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.